Belite Bio Shareholders Approve All Proposed Resolutions
Ticker: BLTE · Form: 6-K · Filed: Apr 15, 2025 · CIK: 1889109
| Field | Detail |
|---|---|
| Company | Belite Bio, INC (BLTE) |
| Form Type | 6-K |
| Filed Date | Apr 15, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, annual-meeting
Related Tickers: BTE
TL;DR
Belite Bio (BTE) shareholders voted YES on everything at the April 15th meeting.
AI Summary
Belite Bio, Inc. announced that all proposed resolutions from its March 18, 2025 Notice of Annual General Meeting were passed at the shareholder meeting held on April 15, 2025. The company is a pharmaceutical preparations firm based in San Diego, California.
Why It Matters
The successful passing of all resolutions indicates shareholder confidence and allows the company to proceed with its planned corporate actions.
Risk Assessment
Risk Level: low — This filing is a routine update on the outcome of an annual general meeting and does not introduce new financial or operational risks.
Key Players & Entities
- Belite Bio, Inc. (company) — Registrant
- March 18, 2025 (date) — Notice of Annual General Meeting date
- April 15, 2025 (date) — Annual General Meeting date
- San Diego, CA (location) — Company headquarters
FAQ
What was the purpose of the Form 6-K filing?
The Form 6-K filing was made to report that all proposed resolutions from Belite Bio, Inc.'s Notice of Annual General Meeting of Shareholders dated March 18, 2025, were duly passed at its 2025 Annual General Meeting held on April 15, 2025.
When was Belite Bio, Inc.'s 2025 Annual General Meeting of Shareholders held?
The 2025 Annual General Meeting of Shareholders for Belite Bio, Inc. was held on April 15, 2025.
What is the company's principal executive office address?
The principal executive office of Belite Bio, Inc. is located at 12750 High Bluff Drive Suite 475, San Diego, CA 92130.
What is the Commission File Number for Belite Bio, Inc.?
The Commission File Number for Belite Bio, Inc. is 001-41359.
What type of issuer is Belite Bio, Inc. according to this filing?
Belite Bio, Inc. is identified as a Foreign Private Issuer pursuant to Rule 13a-16 or 15b-16 of the Securities Exchange Act of 1934.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 15, 2025 regarding BELITE BIO, INC (BLTE).